SCHEMBL2364609

SCHEMBL2364609

CCOC(=O)c1cc(C)n(Cc2cccc(C(=O)OC(C)(C)C)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.46
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 1/20 0.43
ABHD6 Q9BV23 1/20 0.42
POLB P06746 1/20 0.42
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
GAA P10253 2/20 0.41
THRB P10828 1/20 0.41
TP53 P04637 1/20 0.41
FAAH O00519 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2360580 0.86 SMN1; SMN2 (0.47) CYP4F2CYP4A11SMN1; SMN2HPGDKMT2A
SCHEMBL1233306 0.81 SMN1; SMN2 (0.60) SMN1; SMN2KMT2ALMNAPOLBGAA
SCHEMBL29699784 0.81 CYP19A1 (0.57) SMN1; SMN2HPGDKMT2ALMNAMEN1
Bicarbonate SCHEMBL2360581 0.80 SMN1; SMN2 (0.58) SMN1; SMN2KMT2ALMNAPOLBGAA
SCHEMBL2360281 0.79 IDO1 (0.51) SMN1; SMN2KMT2ALMNAMEN1POLB
SCHEMBL15956989 0.76 MEN1 (0.57) SMN1; SMN2HPGDKMT2ALMNAMEN1
SCHEMBL1256757 0.75 HDAC3 (0.42) SMN1; SMN2KMT2ALMNAPOLBCRHBP
SCHEMBL15964667 0.75 ALDH1A1 (0.48) SMN1; SMN2HPGDKMT2ALMNAMEN1
SCHEMBL29699814 0.74 MEN1 (0.61) SMN1; SMN2KMT2AMEN1POLBGAA
SCHEMBL12301533 0.74 SLC7A5 (0.65) SLC7A5CYP4F2CYP4A11SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
EP-2356113-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS HIF1AN, HIF1A, VHL SLC7A5 1808/4885CYP4F2 549/4885CYP4A11 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.